| Autor: |
Ekaterina I Ryabova, Dmitry V. Shcheblyakov, Denis Y. Logunov, Andrey G Botikov, Alexandr L. Gintsburg, Irina A Alekseeva, Ekaterina I. Aksenova, Irina A Favorskaya, Olga L. Voronina, Artem A Derkaev, Natalia N. Ryzhova, Boris S. Naroditsky, M.S. Kunda, Anna V. Kovyrshina, Ilias B Esmagambetov, Daria V Voronina, Daria A. Egorova, Inna V. Dolzhikova, Anna A. Iliukhina, Anastasia I Korobkova, Olga V. Zubkova |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.1101/2021.11.24.469842 |
| Popis: |
Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibodies with a broad spectrum of neutralizing activity is urgently needed. Here we isolated a panel of single-domain antibodies that specifically bind to the receptor-binding domain of SARS-CoV-2 S glycoprotein. Three of the selected antibodies exhibiting most robust neutralization potency were used to generate dimeric molecules. We observed that these modifications resulted in up to a 200-fold increase in neutralizing activity. The most potent heterodimeric molecule efficiently neutralized each of SARS-CoV-2 variant of concern, including Alpha, Beta, Gamma, Delta and Omicron variants. This heterodimeric molecule could be a promising drug candidate for a treatment for COVID-19 caused by virus variants of concern. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
